Learning and research

Webinar presentations: Cardiopulmonary networks: bridging infection and microbiome in pulmonary vascular disease; Inflammasome activation in pulmonary arterial hypertension; Role of oxidative signals in endothelial phenotypes in PH; Spironolactone: an old drug with new tricks; HIPPO/MST signaling via BUB3 and FOXO drives pulmonary vascular cell growth and survival
 

Webinar presentations: Hispanic ethnicity and social determinants of health in pulmonary arterial hypertension; Sirtuin 3 and uncoupling protein2, the missing link between genetics, metabolism, and pulmonary arterial hypertension; Estrogen and portopulmonary hypertension: the Pulmonary Vascular Complications of Liver Disease Study; The right heart network and risk stratification in pulmonary arterial hypertension; Pulmonary hypertension caused by autocrine endothelial signaling
 

Webinar presentations: The PAH microenvironment: lessons learned from tumor microenvironment mechano-induced cell metabolism changes; Identification of arterial and venous morphologic markers in pulmonary arterial hypertension using CT imaging; The keto diet as treatment for pulmonary hypertension associated with obesity; Endothelial transdifferential from exacerbated inflammatory signaling in BMP9 in lung endothelium; The role of pericytes in the pathophysiology of pulmonary arterial hypertension

Webinar presentations: Cellular mechosignaling in pulmonary arterial hypertension; Sex differences in pulmonary arterial hypertension randomized clinical trials; Precapillary pulmonary hypertension and death from COVID-19; Estradiol and estrogen receptor protection of right ventricular function – role of apelin; Prostacyclin reverses right ventricular hypertrophy and dysfunction in severe PAH; Pulmonary vascular complications of heart failure with preserved ejection fraction

Webinar presentations: Autophagy and BMPR2 receptor degradation as the cause of PAH; BMPR1A promotes ID2-ZEB1 interaction to suppress endothelial to mesenchymal transition in PAH; Cardiovascular and pulmonary phenotypes for single and double knockout mice deficient in BMP9 and BMP10; BMPR2 – When and where the animal models match patient disease

Webinar presentations: Autoantibodies as the cause of PAH; Prevalence and effect of myelofibrosis on PAH; Mast cells as the cause of pulmonary vascular remodelling in PAH; B-cell depletion with rituximab for the treatment of systemic sclerosis-associated PH; Emergency myelopoiesis contributes to immune cell exhaustion in pulmonary vascular remodelling

Webinar presentations: Therapeutic efficacy and mechanisms of Drpitor1a in PAH; SNPs for sirtuin3 and uncoupling protein2 are causal of PAH and diabetes disease severity; Mitochondrial control of metabolic, angiogenic, and hematopoietic function in PH onset and progression; Heteroplasmy of wild-type mitochondrial DNA variants causes metabolic heart disease with PH.

Webinar presentations: Update on the Human Lung RNAseq Atlas, Nathan Salomonis, USA; Unsupervised transcriptomic profiling of whole blood shows biologic heterogeneity in iPAH, Allan Lawrie, England; Cellular landscape atlas of pulmonary endarterectomy tissue using single cell RNAseq, Peiran Yang, China; Single cell RNAseq identifies cellular abnormalities in rodent models of PH, Jason Hong, USA.

Webinar presentations: Mechanosensitive cation channels in the pulmonary vascular wall in PAH; Proton exchangers in pulmonary smooth muscle cells in PAH; Pathophysiologic role of mutant potassium channels in pulmonary hypertension; TRPV4 activity in lung microvascular endothelial cells in PAH